Vivos Therapeutics (VVOS) Accounts Payables (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Accounts Payables data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 65.51% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 65.51% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 52.91% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.0 million, up from $1.7 million in the prior quarter.
• Over the last five years, Accounts Payables for VVOS reached as high as $2.5 million in Q1 2024 and fell as low as $644000.0 in Q3 2022.
• Historically, Accounts Payables has averaged $1.5 million across 5 years, with a median of $1.5 million in 2023.
• Across the five-year window, Accounts Payables soared 137.27% in 2023 and tumbled 51.74% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $1.4 million in 2022, then surged by 52.02% to $2.1 million in 2023, then plunged by 48.81% to $1.1 million in 2024, then surged by 52.91% to $1.7 million in 2025, then grew by 18.88% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.0 million in Q1 2026, $1.7 million in Q4 2025, and $2.1 million in Q3 2025.